MX2020006944A - Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. - Google Patents

Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.

Info

Publication number
MX2020006944A
MX2020006944A MX2020006944A MX2020006944A MX2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A
Authority
MX
Mexico
Prior art keywords
cancer
patient
ipsc
prophylactic
therapeutic treatment
Prior art date
Application number
MX2020006944A
Other languages
English (en)
Inventor
Nigel G Kooreman
Joseph C Wu
Lynne Bui
Original Assignee
Khloris Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khloris Biosciences Inc filed Critical Khloris Biosciences Inc
Publication of MX2020006944A publication Critical patent/MX2020006944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En una modalidad, la solicitud describe un método para el tratamiento del cáncer en un paciente, el método comprende una vacunación del paciente con una vacuna, en donde la vacuna comprende una cantidad efectiva de células madre pluripotentes de mamífero obtenidas a partir de una fuente embrionaria, u obtenidas por la reprogramación de células somáticas a partir del paciente, en donde la vacunación comprende el paso de administrar células madre pluripotentes de mamífero al paciente en necesidad de esto; y formulaciones de vacuna para uso en el tratamiento de cáncer.
MX2020006944A 2018-01-02 2019-01-01 Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. MX2020006944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862612826P 2018-01-02 2018-01-02
PCT/US2019/012003 WO2019136038A1 (en) 2018-01-02 2019-01-01 Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer

Publications (1)

Publication Number Publication Date
MX2020006944A true MX2020006944A (es) 2020-11-09

Family

ID=65444317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006944A MX2020006944A (es) 2018-01-02 2019-01-01 Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.

Country Status (10)

Country Link
US (1) US11298380B2 (es)
EP (1) EP3720482A1 (es)
JP (2) JP2021509122A (es)
KR (1) KR20200140238A (es)
CN (1) CN111936161A (es)
AU (1) AU2018399641A1 (es)
CA (1) CA3087254A1 (es)
MX (1) MX2020006944A (es)
SG (1) SG11202006160RA (es)
WO (1) WO2019136038A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018602A2 (pt) * 2018-03-13 2020-12-29 The Board Of Trustees Of The Leland Stanford Junior University Reprogramação celular transiente para reversão de envelhecimento celular
WO2022256277A1 (en) 2021-06-01 2022-12-08 Khloris Biosciences, Inc. Induced pluripotent stem cell-based cancer vaccines
CN113440606A (zh) * 2021-06-02 2021-09-28 深圳市罗湖区人民医院 特异性多能干细胞肿瘤疫苗及其制备方法与应用
CA3229276A1 (en) * 2021-08-13 2023-02-16 Khloris Biosciences, Inc. Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
CA2504451A1 (en) 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1843787B1 (en) 2005-01-28 2011-11-02 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US20150216957A1 (en) * 2012-08-20 2015-08-06 Boris Markosian Placental vaccination therapy for cancer
US20160024469A1 (en) 2013-07-29 2016-01-28 Allan Yang Wu Non-conventional Cellular Based Immunotherapy
BR112018010006A2 (pt) 2015-11-18 2019-02-05 Orbis Health Solutions Llc sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.
CN109689089A (zh) 2016-05-25 2019-04-26 国家医疗保健研究所 治疗癌症的方法和组合物

Also Published As

Publication number Publication date
AU2018399641A1 (en) 2020-07-16
JP2024026069A (ja) 2024-02-28
CN111936161A (zh) 2020-11-13
WO2019136038A1 (en) 2019-07-11
JP2021509122A (ja) 2021-03-18
SG11202006160RA (en) 2020-07-29
US20190290697A1 (en) 2019-09-26
CA3087254A1 (en) 2019-07-11
WO2019136038A4 (en) 2019-08-15
KR20200140238A (ko) 2020-12-15
US11298380B2 (en) 2022-04-12
EP3720482A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
MX2020006944A (es) Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.
MX2018014573A (es) Vacuna contra el virus del zika.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
EP3998341A3 (en) Adenoviral vectors
MX2020011817A (es) Metodos para tratar el linfoma.
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
PH12017500392A1 (en) Medical treatments based on anamorelin
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2020005235A (es) Celula humana transformada y uso de la misma.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019014867A (es) Metodo para tratar un efecto secundario de la inmunoterapia.
WO2020097568A3 (en) Oligosaccharide compositions and methods of use thereof
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EP3541418A4 (en) THERAPY WITH AUTOLOGICAL SOMATIC STEM CELLS, METHOD FOR THE CONTROLLABLE MANUFACTURING OF A THERAPEUTIC COMPOSITION AND PROCEDURE OF ADAPTIVE TREATMENT OF AN IVF PATIENT
CR20220072A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
MX2019007906A (es) Composicion vacunal que comprende un mutante de la interleucina-15 humana.
EP4257128A3 (en) Methods and compounds for the treatment of genetic disease
WO2014063035A3 (en) Treatment of pain using amnion derived adherent cells